

5-5-2010

# Use of a Robust Dehydrogenase from an Archaeal Hyperthermophile in Asymmetric Catalysis—Dynamic Reductive Kinetic Resolution Entry into (S)-Profens

Jacob A. Friest

*University of Nebraska - Lincoln*

Yukari Maezato

*University of Nebraska - Lincoln*

Sylvain Broussy

*University of Nebraska-Lincoln, sylvain.broussy@parisdescartes.fr*

Paul H. Blum

*University of Nebraska-Lincoln, pblum1@unl.edu*

David B. Berkowitz

*University of Nebraska - Lincoln, dberkowitz1@unl.edu*

Follow this and additional works at: <https://digitalcommons.unl.edu/chemistryberkowitz>

 Part of the [Chemistry Commons](#)

---

Friest, Jacob A.; Maezato, Yukari; Broussy, Sylvain; Blum, Paul H.; and Berkowitz, David B., "Use of a Robust Dehydrogenase from an Archaeal Hyperthermophile in Asymmetric Catalysis—Dynamic Reductive Kinetic Resolution Entry into (S)-Profens" (2010). *David Berkowitz Publications*. 11.

<https://digitalcommons.unl.edu/chemistryberkowitz/11>

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in David Berkowitz Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Published in final edited form as:

*J Am Chem Soc.* 2010 May 5; 132(17): 5930–5931. doi:10.1021/ja910778p.

## Use of a Robust Dehydrogenase from an Archaeal Hyperthermophile in Asymmetric Catalysis–Dynamic Reductive Kinetic Resolution Entry into (*S*)-Profens

Jacob A. Friest<sup>‡</sup>, Yukari Maezato<sup>†</sup>, Sylvain Broussy<sup>‡</sup>, Paul Blum<sup>\*,†,§</sup>, and David B. Berkowitz<sup>\*,‡,§</sup>

<sup>‡</sup>Department of Chemistry, University of Nebraska, Lincoln, NE 68588.

<sup>†</sup>School of Biological Sciences, University of Nebraska, Lincoln, NE 68588.

<sup>§</sup>Nebraska Center for Energy Sciences Research, University of Nebraska, Lincoln, NE 68588.

Hyperthermophilic archaea are of great interest in evolutionary microbiology, owing to their ability to withstand high temperatures, and often extremes of pressure, pH and salinity. Enzymes from these organisms<sup>1</sup> may offer particular opportunities for asymmetric synthesis, complementary to approaches with mesophilic enzymes,<sup>2</sup> or those involving enzyme<sup>3</sup> and pathway<sup>4</sup> reengineering. However, perhaps due to a bias that hyperthermophilic enzymes have “narrow substrate specificities,”<sup>5</sup> archaeal extremophiles remain a largely untapped resource in asymmetric synthesis.<sup>6</sup>

Herein, we disclose a remarkably general Dynamic Reductive Kinetic Resolution (DYRKR) entry into (*S*)-profens, including several important NSAIDs. The enzyme employed is alcohol dehydrogenase (ADH)-10, one of 13 annotated ADHs in the hyperthermophile *Sulfolobus solfataricus*. Protein phylogenetic analysis of this paralogous family indicates SsADH-10 is most closely related to homologues in distant taxa (Fig. 1). The highest identity between SsADH-10 and any other SsADHs is only 34%, suggesting that the SsADH family was established prior to the emergence of other archaeal lineages. Though not described as such, the SsADH-10 appears to be the only SsADH isozyme for which structural information is available in the pdb.<sup>7</sup>

The requisite, 2-arylpropionaldehydes were readily assembled via Pd(0)-catalyzed arylation of *t*-butyl propionate under Buchwald-Hartwig-type<sup>8</sup> conditions, followed by reduction to the aldehyde (LDBBA<sup>9</sup> or LAH/DMP oxid-see SI). Optimal DYRKR conditions (Table 1-80°C, pH 9) led to efficient throughput of *rac*-aldehyde to the (*S*)-2-arylpropionaldehyde, particularly with *m*- and *p*-substitution. Notably, (*S*)-profenols corresponding to the NSAIDs naproxen (**3b**, scaled to 1 gram @ 98% yield and 95% ee), ibuprofen (**3d**, IP), flurbiprofen (**3h**, FIP), fenoprofen (**3j**, FP) and ketoprofen (**3l**, KP) were obtained in excellent yields (up to 96%) and high enantioselectivity (up to 99 %).

Naproxen is FDA-approved as the active (*S*)-antipode. While most individuals can invert (*R*)-ibuprofen to the (*S*)-antipode, the pathway is inefficient for KP<sup>10a</sup> and FIP.<sup>10b</sup> Moreover, the recent observation that the profen-CoA thioester intermediates inhibit G6PDH,<sup>10c</sup> argues for “chiral switching” to single (*S*)-antipodes.<sup>10d</sup> Entries into (*S*)-profens<sup>11,12</sup> include asymmetric

dberkowitz1@unl.edu; pblum1@unl.edu.

**Supporting Information Available:** Details of SsADH-10 expression, synthesis, spectra, DYRKR and modeling. This material is available free of charge via the Internet at <http://pubs.acs.org>.

hydrogenation (NP 98% ee, IP 97% ee),<sup>11g</sup> and hydroformylation (IP, 92% ee).<sup>11f</sup> DKR processes include enantioselective crystallization (NP >99% ee),<sup>11b</sup> DYKR with H<sub>2</sub> as reductant under Ru(II) catalysis (IP 92% ee),<sup>11d</sup> and lipase/Ru(II)-mediated-DKR of allylic acetates, followed by Cu-mediated Grignard-arylation (FIP 97% ee;<sup>11c</sup> Knochel arylation:<sup>11e</sup> IP 97% ee). The hydrovinylation/oxidation approach is impressive (IP, FP, FIP, NP >96% ee),<sup>11a</sup> but access to KP requires late stage arylation. Thus, the broad side chain tolerance of SsADH-10 makes the method presented here among the most generally (*S*)-selective.

To explore how these extended hydrophobic substrates bind to SsADH-10, docking was carried out (Fig. 2) for the (*S*)-antipodes of flurbiprofenal, naproxenal, ketoprofenal and fenoprofenal. A detailed discussion of the approach and results is provided in the SI. Briefly, W95 is seen as enforcing (*S*)-selectivity, with ligands clustering into two distinct distal ring binding modes. “Channel-gating”-L272 and L295 appear to form a hydrophobic pocket for naproxenal and flurbiprofenal. For the more flexible ketoprofenal and fenoprofenal, edge-to-face interactions with W117 and F49 are proposed.

From a practical viewpoint, we have also found that SsADH-10 may be engaged in a “thermal recycling” approach that may be generalizable to other hyperthermophilic enzymes. Namely, while 30 vol% cosolvent is often needed to dissolve hydrophobic DH substrates,<sup>13</sup> we use a higher T (80°C) @ just 5% EtOH (solvent and biorenewable reductant). Importantly, upon completion of the reaction, cooling to rt allows the product to precipitate and be collected by filtration (*see TOC graphic and SI*). Reclaimed SsADH may be recycled (5 cycles @ 94-96 % ee). Given the growing interest in thermophilic enzymes in synthesis,<sup>1,14</sup> and in engineering thermostability into mesophilic enzymes,<sup>15</sup> this “thermal switching” approach is likely to find broad application, well beyond the domain of geothermal dehydrogenases.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors thank David L. Nelson for helpful consultation and the Nebraska Center for Energy Research Sciences, and the NSF (CHE-0911732 to DBB) for support. We thank the NSF (CHE-0091975, MRI-0079750) & NIH (SIG-1-510-RR-06307) for NMR facilities, & the NIH (RR016544) for lab renovation.


## REFERENCES

- (1). Atomi H. *Curr. Opin. Chem. Biol* 2005;9:166–173. [PubMed: 15811801]
- (2). Broussy S, Cheloha RW, Berkowitz DB. *Org. Lett* 2009;11:305–8. [PubMed: 19128188]
- (3) (a). Reetz MT, Wu S. *J. Am. Chem. Soc* 2009;131:15424–15432. [PubMed: 19807086] (b) Kourist R, Hohne M, Bornscheuer UT. *Chem. Unserer Zeit* 2009;43:132–142. (c) Kazlauskas RJ, Bornscheuer UT. *Nat. Chem. Biol* 2009;5:526–529. [PubMed: 19620988] (d) Jackel C, Kast P, Hilvert D. *Annu. Rev. Biophys* 2008;37:153–173. [PubMed: 18573077] (e) Reetz MT, Wang L-W, Bocla M. *Angew. Chem., Int. Ed* 2006;45:1236–1241. (f) Qian Z, Lutz S. *J. Am. Chem. Soc* 2005;127:13466–13467. [PubMed: 16190688]
- (4) (a). Ran N, Frost JW. *J. Am. Chem. Soc* 2007;129:6130–6139. [PubMed: 17451239] (b) Li W, Xie D, Frost JW. *J. Am. Chem. Soc* 2005;127:2874–2882. [PubMed: 15740122] (c) Moradian A, Benner SA. *J. Am. Chem. Soc* 1992;114:6980–7.
- (5). Radianingtyas H, Wright PC. *FEMS Microbiol. Rev* 2003;27:593–616. [PubMed: 14638414]
- (6) (a). Moore JC, Pollard DJ, Kosjek B, Devine PN. *Acc. Chem. Res* 2007;40:1412–1419. [PubMed: 18052114] (b) Anderson BA, Hansen MM, Harkness AR, Henry CL, Vicenzi JT, Zmijewski MJ. *J. Am. Chem. Soc* 1995;117:12358–12359.

- (7) (a). For elegant biophysical studies, see: Esposito L, Bruno I, Sica F, Carlo A, Raia, Giordano A, Rossi M, Mazzarella L, Zagari A. *Biochemistry* 2003;42:14397–14407. [PubMed: 14661950] ; (b) Esposito L, Sica F, Raia CA, Giordano A, Rossi M, Mazzarella L, Zagari A. *J. Mol. Biol* 2002;318:463–477. [PubMed: 12051852]
- (8) (a). Moradi WA, Buchwald SL. *J. Am. Chem. Soc* 2001;123:7996–8002. [PubMed: 11506555] (b) Jorgensen M, Lee S, Liu X, Wolkowski JP, Hartwig JF. *J. Am. Chem. Soc* 2002;124:12557–12565. [PubMed: 12381200]
- (9). Kim MS, Choi YM, An DK. *Tetrahedron Lett* 2007;48:5061–5064.
- (10) (a). Jamali F, Brocks DR. *Clin. Pharmacokin* 1990;19:197–217. (b) Geisslinger G, Loetsch J, Menzel S, Kobal G, Brune K. *Br. J. Clin. Pharmacol* 1994;37:392–394. [PubMed: 8018462] (c) Asensio C, Levoine N, Guillaume C, Guerquin M-J, Rouguieg K, Chretien F, Chapleur Y, Netter P, Minn A, Lapique F. *Biochem. Pharm* 2007;73:405–416. [PubMed: 17094951] (d) Agranat I, Caner H, Caldwell J. *Nature: Rev. Drug Disc* 2002;1:753–768.
- (11) (a). Smith CR, RajanBabu TV. *J. Org. Chem* 2009;74:3066–3072. [PubMed: 19317393] (b) Noorduyn WL, Kaptein B, Meekes H, van Enckevort WJP, Kellogg RM, Vlieg E. *Angew. Chem., Int. Ed* 2009;48:4581–4583. (c) Norinder J, Bogar K, Kanupp L, Baekvall J-E. *Org. Lett* 2007;9:5095–5098. [PubMed: 17956114] (d) Li X, List B. *Chem. Commun* 2007:1739–1741. (e) Harrington-Frost N, Leuser H, Calaza MI, Kneisel FF, Knochel P. *Org. Lett* 2003;5:2111–2114. [PubMed: 12790541] (f) Nozaki K, Sakai N, Nanno T, Higashijima T, Mano S, Horiuchi T, Takaya H. *J. Am. Chem. Soc* 1997;119:4413–4423. (g) Uemura T, Zhang X, Matsumura K, Sayo N, Kumobayashi H, Ohta T, Nozaki K, Takaya H. *J. Org. Chem* 1996;61:5510–5516.
- (12). During these studies, one example (mesophilic HLADH, ibuprofenal) of a related DYRK was reported: Giacomini D, Galletti P, Quintavalla A, Gucciardo G, Paradisi F. *Chem. Commun* 2007:4038–4040.
- (13). Musa MM, Ziegelmann-Fjeld KI, Vieille C, Zeikus JG, Phillips RS. *J. Org. Chem* 2007;72:30–34. [PubMed: 17194078]
- (14) (a). Voss CV, Gruber CC, Faber K, Knaus T, Macheroux P, Kroutil W. *J. Am. Chem. Soc* 2008;130:13969–13972. [PubMed: 18821754] (b) Musa MM, Ziegelmann-Field KI, Vieille C, Zeikus JG, Phillips RS. *Angew. Chem., Int. Ed* 2007;46:3091–3094. (c) van den Burg B. *Curr. Opin. Microbiol* 2003;6:213–218. [PubMed: 12831896]
- (15) (a). Shaw BF, Schneider GF, Bilgic B, Kaufman GK, Neveu JM, Lane WS, Whitelegge JP, Whitesides GM. *Protein Sci* 2008;17:1446–1455. [PubMed: 18451358] (b) Reetz MT, Carballeira JD, Vogel A. *Angew. Chem., Int. Ed* 2006;45:7745–7751.



Protein phylogeny of the SsADH proteins. A consensus neighbor joining distance tree is shown of all SsADHs and homologues of highest sequence identity in related taxa. Distances are indicated by the bar (lower left corner) and represent 10 substitutions per 100 residues. Percent occurrence among 100 trees was greater than 50% for all nodes except those indicated with an asterisk.






**Figure 2.**


Structures of thermally relaxed (GROMACS 4.07) SsADH-10 (from 1R37) to which has been docked (Autodock Vina - left to right-): (i) (*S*)-flurbiprofenal (ii) (*S*)-naproxenal (iii) (*S*)-ketoprofenal and (iv) (*S*)-fenoprofenal (Zn ligation sphere: H68, C38, C154 and substrate carbonyl)

Table 1

SsADH10-Mediated DYRKR Entry into Profenols




| Cpd No. | DYRKR Product <sup>a</sup>  | t(h) | Yield (%) <sup>b</sup> |
|---------|---|------|------------------------|
| 3a      |  | 18   | 57%                    |
| 3b      |  | 18   | 96%                    |




| Cpd No. | DYRKR Product <sup>a</sup> | t(h) | Yield (%) <sup>b</sup> |
|---------|----------------------------|------|------------------------|
| 3c      |                            | 18   | 90%                    |
| 3d      |                            | 18   | 92%                    |
| 3e      |                            | 18   | 74%                    |






| Cpd<br>No. | DYRKR<br>Product <sup>a</sup> | t(h) | Yield<br>(%) <sup>b</sup> |
|------------|-------------------------------|------|---------------------------|
|------------|-------------------------------|------|---------------------------|




2f

(redn not obsd)

18 recvd S




| Cpd No. | DYRKR Product <sup>a</sup> | t(h) | Yield (%) <sup>b</sup> |
|---------|----------------------------|------|------------------------|
|---------|----------------------------|------|------------------------|



3g

18 99%



| Cpd No. | DYRKR Product <sup>a</sup> | t(h) | Yield (%) <sup>b</sup> |
|---------|----------------------------|------|------------------------|
| 3h      |                            | 18   | 77%                    |
| 3i      |                            | 24   | 55%                    |
| 3j      |                            | 12   | 85%                    |
| 3k      |                            | 18   | 95%                    |
| 3l      |                            | 18   | 85%                    |

<sup>a</sup> DYRKR performed on a 1 mmol scale (1 mol% NADH; 5 vol% EtOH)

<sup>b</sup> Isolated yields

<sup>c</sup> ee's by chiral LC or GC. Blue - profen drug precursor.